The chemical name you provided, **1-(3-chloro-4-methoxyphenyl)-3-[2-(4-methyl-1-piperidinyl)ethyl]thiourea**, refers to a specific organic compound. This compound is a **thiourea derivative**, meaning it contains the functional group -NH-C(=S)-NH-.
It's important to understand that this compound is not a widely studied or established drug. It's likely a **synthetic compound**, potentially developed in a research setting for a specific purpose.
**Here's why such compounds can be important for research:**
* **Drug Discovery:** Researchers often synthesize and test a large number of compounds to identify potential new drugs. This specific compound might have shown promising activity in a preliminary screen for a particular disease or condition.
* **Structure-Activity Relationships (SAR):** By studying the effects of modifications to the chemical structure of a compound, researchers can understand how different parts of the molecule contribute to its activity. This compound might be part of a series of related compounds being investigated to optimize their biological activity.
* **Biological Target Identification:** The compound may have been designed to interact with a specific protein or enzyme in the body. Understanding how it interacts with its target can provide valuable insights into the biological processes involved in a disease.
* **Pharmacokinetic Studies:** Researchers might investigate how the compound is absorbed, distributed, metabolized, and excreted in the body. This information is crucial for developing a safe and effective drug.
**To know the exact importance of this specific compound, you would need more information about its context:**
* **What research group synthesized it?**
* **What was the purpose of its synthesis?**
* **What biological activity was it tested for?**
Without this information, it's impossible to say why this particular thiourea derivative is important. It's likely a research tool rather than a drug in development.
ID Source | ID |
---|---|
PubMed CID | 972870 |
CHEMBL ID | 1340607 |
CHEBI ID | 114793 |
Synonym |
---|
MLS000664868 , |
smr000294826 |
n-(3-chloro-4-methoxyphenyl)-n'-[2-(4-methyl-1-piperidinyl)ethyl]thiourea |
STK327898 |
1-(3-chloro-4-methoxyphenyl)-3-[2-(4-methylpiperidin-1-yl)ethyl]thiourea |
CHEBI:114793 |
AKOS003599565 |
HMS2696I18 |
CHEMBL1340607 , |
bdbm88757 |
1-(3-chloro-4-methoxy-phenyl)-3-[2-(4-methylpiperidino)ethyl]thiourea |
1-(3-chloro-4-methoxyphenyl)-3-[2-(4-methyl-1-piperidinyl)ethyl]thiourea |
1-(3-chloranyl-4-methoxy-phenyl)-3-[2-(4-methylpiperidin-1-yl)ethyl]thiourea |
cid_972870 |
Q27196198 |
bdbm50252266 |
Class | Description |
---|---|
thioureas | Compounds of general formula RR'NC(=S)NR''R'''. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 17.7828 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 14.0919 | 0.1409 | 11.1940 | 39.8107 | AID2451 |
glp-1 receptor, partial | Homo sapiens (human) | Potency | 8.9125 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
phosphopantetheinyl transferase | Bacillus subtilis | Potency | 2.5119 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 10.0000 | 0.5318 | 15.4358 | 37.6858 | AID504845 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 11.2202 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 89.1251 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 0.0794 | 0.0398 | 16.7842 | 39.8107 | AID1454 |
serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 10.6213 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 63.0957 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 20.0850 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
geminin | Homo sapiens (human) | Potency | 12.8511 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 10.0000 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
ATP-dependent phosphofructokinase | Trypanosoma brucei brucei TREU927 | Potency | 26.8545 | 0.0601 | 10.7453 | 37.9330 | AID485367 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
tyrosine-protein phosphatase non-receptor type 11 isoform 1 | Homo sapiens (human) | IC50 (µMol) | 0.9990 | 0.1600 | 3.3759 | 9.8800 | AID602367 |
dual specificity protein phosphatase 3 | Homo sapiens (human) | IC50 (µMol) | 0.7200 | 0.4000 | 9.3610 | 90.0000 | AID602374 |
tyrosine-protein phosphatase non-receptor type 5 isoform a | Homo sapiens (human) | IC50 (µMol) | 14.7000 | 4.1700 | 12.5457 | 19.0000 | AID602372; AID624207 |
tyrosine-protein phosphatase non-receptor type 22 isoform 1 | Homo sapiens (human) | IC50 (µMol) | 43.8730 | 0.4800 | 2.6449 | 8.3270 | AID624241 |
Acetylcholinesterase | Homo sapiens (human) | IC50 (µMol) | 12.0000 | 0.0000 | 0.9332 | 10.0000 | AID1452665 |
Acetylcholinesterase | Anopheles gambiae (African malaria mosquito) | IC50 (µMol) | 12.4800 | 0.0436 | 0.3821 | 0.9600 | AID1452663; AID1452669 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
amyloid-beta binding | Acetylcholinesterase | Homo sapiens (human) |
acetylcholinesterase activity | Acetylcholinesterase | Homo sapiens (human) |
cholinesterase activity | Acetylcholinesterase | Homo sapiens (human) |
protein binding | Acetylcholinesterase | Homo sapiens (human) |
collagen binding | Acetylcholinesterase | Homo sapiens (human) |
hydrolase activity | Acetylcholinesterase | Homo sapiens (human) |
serine hydrolase activity | Acetylcholinesterase | Homo sapiens (human) |
acetylcholine binding | Acetylcholinesterase | Homo sapiens (human) |
protein homodimerization activity | Acetylcholinesterase | Homo sapiens (human) |
laminin binding | Acetylcholinesterase | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
extracellular region | Acetylcholinesterase | Homo sapiens (human) |
basement membrane | Acetylcholinesterase | Homo sapiens (human) |
extracellular space | Acetylcholinesterase | Homo sapiens (human) |
nucleus | Acetylcholinesterase | Homo sapiens (human) |
Golgi apparatus | Acetylcholinesterase | Homo sapiens (human) |
plasma membrane | Acetylcholinesterase | Homo sapiens (human) |
cell surface | Acetylcholinesterase | Homo sapiens (human) |
membrane | Acetylcholinesterase | Homo sapiens (human) |
neuromuscular junction | Acetylcholinesterase | Homo sapiens (human) |
synaptic cleft | Acetylcholinesterase | Homo sapiens (human) |
synapse | Acetylcholinesterase | Homo sapiens (human) |
perinuclear region of cytoplasm | Acetylcholinesterase | Homo sapiens (human) |
side of membrane | Acetylcholinesterase | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1452669 | Inhibition of recombinant full length Anopheles gambiae AChE1 G122S mutant expressed in baculovirus-infected Sf9 insect cells using acetylthiocholine iodide as substrate measured over 60 secs by Ellman's method | 2017 | European journal of medicinal chemistry, Jul-07, Volume: 134 | N-Aryl-N'-ethyleneaminothioureas effectively inhibit acetylcholinesterase 1 from disease-transmitting mosquitoes. |
AID1452663 | Inhibition of recombinant full length Anopheles gambiae AChE1 expressed in baculovirus-infected Sf9 insect cells using acetylthiocholine iodide as substrate measured over 60 secs by Ellman's method | 2017 | European journal of medicinal chemistry, Jul-07, Volume: 134 | N-Aryl-N'-ethyleneaminothioureas effectively inhibit acetylcholinesterase 1 from disease-transmitting mosquitoes. |
AID1452665 | Inhibition of recombinant human AChE expressed in HEK293F cells using acetylthiocholine iodide as substrate measured over 60 secs by Ellman's method | 2017 | European journal of medicinal chemistry, Jul-07, Volume: 134 | N-Aryl-N'-ethyleneaminothioureas effectively inhibit acetylcholinesterase 1 from disease-transmitting mosquitoes. |
AID1452666 | Inhibition of recombinant full length Aedes aegypti AChE1 expressed in baculovirus-infected Sf9 insect cells at 1 mM using acetylthiocholine iodide as substrate measured over 60 secs by Ellman's method | 2017 | European journal of medicinal chemistry, Jul-07, Volume: 134 | N-Aryl-N'-ethyleneaminothioureas effectively inhibit acetylcholinesterase 1 from disease-transmitting mosquitoes. |
AID1452664 | Inhibition of recombinant full length Aedes aegypti AChE1 expressed in baculovirus-infected Sf9 insect cells using acetylthiocholine iodide as substrate measured over 60 secs by Ellman's method | 2017 | European journal of medicinal chemistry, Jul-07, Volume: 134 | N-Aryl-N'-ethyleneaminothioureas effectively inhibit acetylcholinesterase 1 from disease-transmitting mosquitoes. |
AID1452661 | Inhibition of recombinant full length Anopheles gambiae AChE1 expressed in baculovirus-infected Sf9 insect cells at 1 mM using acetylthiocholine iodide as substrate measured over 60 secs by Ellman's method | 2017 | European journal of medicinal chemistry, Jul-07, Volume: 134 | N-Aryl-N'-ethyleneaminothioureas effectively inhibit acetylcholinesterase 1 from disease-transmitting mosquitoes. |
AID1452668 | Selectivity ratio of IC50 for recombinant human AChE expressed in HEK293F cells to IC50 for recombinant full length Anopheles gambiae AChE1 expressed in baculovirus-infected Sf9 insect cells | 2017 | European journal of medicinal chemistry, Jul-07, Volume: 134 | N-Aryl-N'-ethyleneaminothioureas effectively inhibit acetylcholinesterase 1 from disease-transmitting mosquitoes. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (16.67) | 29.6817 |
2010's | 4 (66.67) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.35) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |